Christopher Lewis Stone

Executive

US·SEC (Form 4)

PDL Biopharma, Inc.

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 28 Jan 2016 for PDL BIOPHARMA, INC.. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Christopher Lewis Stone: trading record in brief

All filings by Christopher Lewis Stone on record concern PDL Biopharma, Inc. Over a trading history stretching from 10 April 2014 to 26 January 2016, the count stands at 2 filings.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The latest filing, published on 28 January 2016, reports a share grant in PDL Biopharma, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.